← Back to Clinical Trials
Recruiting NCT04235517

NCT04235517 RSA Study on the Behaviour of the Growth Plate During and After Temporary Hemi-epiphysiodesis and Epiphysiodesis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04235517
Status Recruiting
Phase
Sponsor Oslo University Hospital
Condition Anisomelia
Study Type OBSERVATIONAL
Enrollment 10 participants
Start Date 2017-01
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 16 Years
Study Type OBSERVATIONAL
Interventions
Temporary hemi-epiphysiodesis or epiphysiodesis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10 participants in total. It began in 2017-01 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

By using radiostereometric analysis (RSA) we will be able to study growth during and after temporary epiphysiodesis and with great accuracy be able to detect asymmetric growth following this procedure. By using the same method we also want to analyse patients with axial deviations operated with guided growth (tension band plating) to study the growth during and after the procedure and be able to set the correct timing for removal of the implant.

Eligibility Criteria

Inclusion Criteria: * Children with idiopathic axial deviations in the lower extremities * Children with limb length discrepancys where timing of epiphysiodesis is difficult because of a big discrepancy in skeletal age and chronological age Exclusion Criteria: * Children with axial deviations and pathological physis

Contact & Investigator

Central Contact

Anne B Breen, MD

✉ anneb3@ous-hf.no

📞 92226905

Principal Investigator

Joachim Horn, MD,PHD

STUDY CHAIR

Oslo Unversity Hospital

Frequently Asked Questions

Who can join the NCT04235517 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 16 Years, studying Anisomelia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04235517 currently recruiting?

Yes, NCT04235517 is actively recruiting participants. Contact the research team at anneb3@ous-hf.no for enrollment information.

Where is the NCT04235517 trial being conducted?

This trial is being conducted at Oslo, Norway.

Who is sponsoring the NCT04235517 clinical trial?

NCT04235517 is sponsored by Oslo University Hospital. The principal investigator is Joachim Horn, MD,PHD at Oslo Unversity Hospital. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology